Note Added in response to 2020 Twitter mob attack which attempts to misrepresent my views:
This post discusses a Science News article that misrepresented the activities of the startup Genomic Prediction (GP), which I helped to found. The news article wrongly conflated screening embryos for intelligence (which GP does NOT do; this is not really possible technically at the moment -- there is still too much noise in the predictors) with testing for unusual disease risk (which GP does).
Media outlets tend to be very sloppy in confusing these two types of screening. Screening for disease risk is very common in IVF. About 2 million embryos per year undergo some level of genetic screening. The original Science News article was corrected after a tedious interaction with the editor. There are many other news articles out there that make the same mistake, but we expected something better from Science. By contrast, The Economist article is very accurate and concise.
#####################################################
Modern genetics will improve health and usher in “designer” children (Economist), which I linked to in the last post, does an excellent job of covering the scientific, technical, and ethical issues raised by recent advances in polygenic risk prediction and embryo screening.
The author, Ananyo Bhattacharya, is an experienced science writer with (if I recall correctly) a degree in Physics. His forthcoming book is an ambitious scientific / intellectual history of John von Neumann!
What did Ananyo get right in his article?
1. He gives an overview of polygenic risk scores (PRS) and the underlying science behind GWAS studies and construction of risk predictors
2. He describes how PRS will have important applications in health care as well as in IVF
3. He discusses the important ethical and societal aspects of embryo screening
As someone who works in this area, I can say that I don't know of any popular work that combines the clarity, precision, and concision of this article (3 pages).
Unfortunately, not all journalism reaches this high standard.
For example, a really terrible ("click-bait")
article appeared in the News section of Science recently, which conflated embryo screening to reduce disease risk with the optimization of complex traits such as IQ or height. I had numerous email exchanges with the writer (a self-described "non-scientist"), running to thousands of words, and including references to published work on disease risk reduction from genomic prediction. The resulting story was irresponsible, and very confusing to readers. I can judge this directly and empirically from communications I received in reaction to it.
Here is the letter we submitted to Science in response to the article. We do not know whether our letter will be published, but the News editor
has already made significant revisions to the original article in response to our complaints.
Dear Editor,
Your news article Screening embryos for IQ and other complex traits is premature, study concludes (Oct 24 2019) contained significant errors, which we correct below.
Each year roughly 2 million IVF embryos are genetically screened worldwide. In many developed countries, a significant fraction of all babies are born via IVF (e.g., almost 10% in Denmark). Reproductive health and IVF are serious matters and deserve serious journalism, not the inaccurate sensationalism of your article. Errors persist in the article even after numerous email exchanges (consisting of thousands of words of text, including references to published research) with your writer, informing your journalist clearly of these misrepresentations.
1. Your article failed to cite published work that shows significant risk reduction for complex disease conditions using polygenic predictors to select between sibling embryos. These results, which we emphasized many times to the writer, explicitly contradict this entire paragraph of the article:
The work "is the first to empirically test the viability of screening embryos" for traits that are influenced by many genes, says sociologist and demographer Melinda Mills of the University of Oxford in the United Kingdom. Such embryo screening goes beyond today's testing for single-gene disorders and currently "isn't plausible," she concludes.
[ Note: this paragraph has been altered now in the Science article. The original is given above. Science added this to the modified article, but still without referencing our work: *Clarification, 5 November, 10:05 a.m.: This story has been updated to clarify the context of a quote from Melinda Mills to emphasize that she was referring to screening for desirable traits, not disease risks. ]
Carmi et al. is not the first to empirically test embryo screening. Our published work predates it. Furthermore, Carmi’s work uses far less sibling data than our preceding work - an order of magnitude fewer siblings, 2-3 orders of magnitude fewer families (28 vs several thousand). Carmi’s analysis relies primarily on “simulated” data, ours is 100% empirical. We made your writer abundantly aware of the published work validating differentiation of real siblings (not “synthetic genomes”) by polygenic disease status, linking to it in email correspondence:
“You would be negligent to cite a BioRxiv preprint without thoroughly addressing our peer-reviewed, formally published work in the field, significantly predating this preprint.”
Your article misleads the reader to think that the dozens of IVF clinics and laboratories working with Genomic Prediction to screen embryos for complex (polygenic) disease risk do so without detailed, published validation. This is an irresponsible, unprofessional, and dangerous misrepresentation. We reserve the right to seek damages.
2. The article, and especially the title of the article, conflates screening embryos for disease with optimizing embryos for IQ, and gives the false impression that Carmi address the use-case of our patients: relative risk reduction of disease. This is misleading, as we repeatedly emphasized in writing with your journalist: “You will misrepresent our test if you fail to make this distinction...” , etc. The reader is misled by the article - especially the headline - to think that Carmi’s work addresses the current polygenic use-case of screening embryos for relative risk reduction of disease, rather than Carmi’s futuristic thought experiment of IQ optimization. This conflation is irresponsible, and a disservice to everyone, particularly to the IVF families using screening to reduce polygenic disease risk.
From IVF scientific pioneer Prof. Simon Fishel, external to Genomic Prediction. Fishel is former Deputy Scientific Director of the world's first IVF clinic, which included Nobel prize winning colleagues Dr. Steptoe and Dr. Edwards. His response to the Science article: "IVF itself was a revolutionary new technology that also endured an initial response of similar misrepresentation. There is no reason to repeat the mistakes of the past; Science should aim to convey the state of the field with less inaccuracy."
We ask that you publish this letter, and publish a correction to the article. We also ask that you recommit yourself to serious science reporting.
Sincerely,
Prof. Stephen Hsu
Dr. Nathan Treff
Laurent C. A. Melchior Tellier
Dr. Jia Xu
Prof. Simon Fishel
Note, I commented on Carmi et al. when it first appeared,
here. This commentary was one of the first things I shared with the journalist and it makes very clear the difference between optimization of traits such as height or IQ (which Genomic Prediction does not do) and disease risk reduction (which is the main focus of our report).
The following is from an email I sent to the writer and editors:
... disease conditions are themselves complex traits and are typically referred to as such, so the risk of confusion is high. From the Wikipedia article on Complex Traits: "Examples of complex traits include height, circadian rhythms, enzyme kinetics, and many diseases including diabetes and Parkinson's disease." ...
Hence the title of the Science article
Screening embryos for IQ and other complex traits is premature, study concludes is extremely misleading.
The most important scientific point:
we have demonstrated that polygenic predictors can differentiate between two adult siblings, one with the disease and the other without. This is the gold standard validation relevant for embryo selection --
the predictor can identify from DNA alone the sibling with higher risk of the disease. The evidence is very strong that we can reduce disease risk through embryo screening, and IVF parents have a right to make use of this capability.
In an era of rapid scientific progress and technological change, the public deserves careful, accurate reporting -- not sensationalism.
For future reference, here are simple sentences which a journalist can include in any future article on this topic:
Published validation studies, using genomic data from thousands of families, have shown that polygenic scores can predict which of two adult siblings has the disease, and which one is healthy. It is reasonable to conclude that these predictors can reduce disease risk through IVF embryo screening.
